Question 1

What is AstraZeneca's P/S ratio?

Accepted Answer

AstraZeneca (AZN) P/S ratio is 4.8× as of June 5, 2026. The ratio is calculated by dividing market capitalisation by trailing twelve-month revenue, using USD-normalised financials (IAS 21 exchange-rate translation for non-USD reporters).

Question 2

How is the P/S ratio calculated?

Accepted Answer

P/S = Market Capitalisation ÷ Trailing Twelve-Month (TTM) Revenue, or equivalently Share Price ÷ TTM Revenue Per Share. All inputs are sourced from audited GAAP/IFRS filings and translated to USD using period-end exchange rates so the multiple is comparable across companies and currencies.

Question 3

What is the P/S ratio?

Accepted Answer

The price-to-sales (P/S) ratio compares a company's market capitalisation to its trailing twelve-month (TTM) revenue. It is calculated as market cap ÷ TTM revenue (equivalent to share price ÷ TTM revenue per share). Because the denominator (revenue) cannot be negative, P/S is widely used to value unprofitable or pre-profit companies and to make cross-sector comparisons.

Question 4

What is a good P/S ratio for AstraZeneca?

Accepted Answer

A "good" P/S depends heavily on profit margin and growth: software and other high-margin businesses often command 5–15× sales, while low-margin retailers and commodity producers typically trade below 1×. Compare against sector peers rather than absolute thresholds. For AstraZeneca specifically, the relevant sector benchmark is the current sector median of 3.5×.

Question 5

Is AstraZeneca's P/S ratio high or low?

Accepted Answer

AstraZeneca's P/S ratio of 4.8× is above its own 5-year average of 4.6× and above the sector median of 3.5×. That places the current reading at the 56th percentile of its 10-year history. A higher multiple usually reflects stronger expected growth, lower perceived risk, or higher returns on capital; a lower multiple reflects the opposite.

Question 6

What is AstraZeneca's historical P/S ratio range?

Accepted Answer

In the available daily series, AstraZeneca (AZN) P/S ratio has ranged from a low of 1.6× in 2009 to a high of 5.9× in 2021. The 5-year average is 4.6× and the 5-year median is 4.7×.

Question 7

What was AstraZeneca's P/S ratio in 2025?

Accepted Answer

AstraZeneca (AZN) P/S ratio at the end of 2025 was 4.6×. Annual values reflect the multiple on the last trading day of each calendar year, using the trailing twelve-month revenue figure available at that date.

Question 8

Why does AstraZeneca's P/S ratio change over time?

Accepted Answer

Valuation multiples move with two inputs: the numerator (market capitalisation, which tracks the share price) and the denominator (revenue). Share-price changes — driven by interest rates, earnings expectations, risk appetite, and broader market sentiment — typically dominate short-term moves, while changes in the underlying fundamental drive the longer-term trend. As a result, the ratio can rise during stock-price rallies even if the business itself has not become more valuable, and fall during sell-offs even when fundamentals are improving.


2025	$272.02B	$58.74B	4.6×	+0.9×	Dec 31, 2025
2024	$201.50B	$54.07B	3.7×	-0.8×	Dec 31, 2024
2023	$205.72B	$45.81B	4.5×	-0.3×	Dec 31, 2023
2022	$211.00B	$44.35B	4.8×	-0.0×	Dec 31, 2022
2021	$179.22B	$37.42B	4.8×	-0.2×	Dec 31, 2021
2020	$132.51B	$26.62B	5.0×	-0.5×	Dec 31, 2020
2019	$132.51B	$24.38B	5.4×	+1.1×	Dec 31, 2019
2018	$96.24B	$22.09B	4.4×	+0.5×	Dec 31, 2018
2017	$86.83B	$22.46B	3.9×	+0.9×	Dec 31, 2017
2016	$68.15B	$23.00B	3.0×	-0.5×	Dec 31, 2016
2015	$85.51B	$24.71B	3.5×	+0.1×	Dec 31, 2015
2014	$88.89B	$26.51B	3.4×	+0.5×	Dec 31, 2014
2013	$73.80B	$25.71B	2.9×	+0.8×	Dec 31, 2013
2012	$58.90B	$27.97B	2.1×	+0.3×	Dec 31, 2012
2011	$60.73B	$33.59B	1.8×	-0.2×	Dec 31, 2011
2010	$65.45B	$33.27B	2.0×	-0.1×	Dec 31, 2010
2009	$67.97B	$32.80B	2.1×	+0.2×	Dec 31, 2009
2008	$59.37B	$31.60B	1.9×	-0.2×	Dec 31, 2008
2007	$62.39B	$29.56B	2.1×	-1.0×	Dec 31, 2007
2006	$81.31B	$26.48B	3.1×	-0.1×	Dec 31, 2006
2005	$76.74B	$23.95B	3.2×	+0.4×	Dec 31, 2005
2004	$60.23B	$21.43B	2.8×	-1.4×	Dec 31, 2004
2003	$80.18B	$18.85B	4.3×	+0.8×	Dec 31, 2003
2002	$60.25B	$17.65B	3.4×	-0.0×	Dec 31, 2002
2001	$81.36B	$23.53B	3.5×	—	Dec 31, 2001


Zimmer Biomet Holdings (ZBH)	2.1×
AptarGroup (ATR)	2.1×
Becton, Dickinson and (BDX)	2.1×
Charles River (CRL)	1.9×
Quest Diagnostics (DGX)	1.9×
IQVIA (IQV)	1.7×
GE HealthCare (GEHC)	1.6×
Labcorp Holdings (LH)	1.6×
HCA Healthcare (HCA)	1.4×
Solventum (SOLV)	1.4×
Viatris (VTRS)	1.1×
Baxter International (BAX)	0.8×
DaVita (DVA)	0.7×
Henry Schein (HSIC)	0.6×
Universal Health Services (UHS)	0.6×
UnitedHealth Group (UNH)	0.5×
Elevance Health (ELV)	0.3×
McKesson (MCK)	0.3×
Cigna (CI)	0.3×
CVS Health (CVS)	0.2×
Cardinal Health (CAH)	0.2×
Cencora (COR)	0.2×
Humana (HUM)	0.2×
Molina Healthcare (MOH)	0.2×
Centene (CNC)	0.1×

P/S Ratio for AstraZeneca (AZN)

P/S Ratio daily chart for AstraZeneca (AZN)

Historical P/S Ratio for AstraZeneca (AZN) from 2001 to 2025

About P/S Ratio at AstraZeneca (AZN)

AstraZeneca P/S Ratio by Year

AstraZeneca P/S Ratio 2025: 4.6×

AstraZeneca P/S Ratio 2024: 3.7×

AstraZeneca P/S Ratio 2023: 4.5×

AstraZeneca P/S Ratio 2022: 4.8×

AstraZeneca P/S Ratio 2021: 4.8×

Sector peers by P/S Ratio — chart

Sector peers by P/S Ratio — table

Frequently asked questions

AstraZeneca (AZN) Key Financials

P/S Ratio daily chart for AstraZeneca (AZN)

Historical P/S Ratio for AstraZeneca (AZN) from 2001 to 2025

About P/S Ratio at AstraZeneca (AZN)

AstraZeneca P/S Ratio by Year

AstraZeneca P/S Ratio 2025: 4.6×

AstraZeneca P/S Ratio 2024: 3.7×

AstraZeneca P/S Ratio 2023: 4.5×

AstraZeneca P/S Ratio 2022: 4.8×

AstraZeneca P/S Ratio 2021: 4.8×

Sector peers by P/S Ratio — chart

Sector peers by P/S Ratio — table

Frequently asked questions

+What is AstraZeneca's P/S ratio?

+How is the P/S ratio calculated?

+What is the P/S ratio?

+What is a good P/S ratio for AstraZeneca?

+Is AstraZeneca's P/S ratio high or low?

+What is AstraZeneca's historical P/S ratio range?

+What was AstraZeneca's P/S ratio in 2025?

+Why does AstraZeneca's P/S ratio change over time?

AstraZeneca (AZN) Key Financials